New study aims to improve blood test accuracy for transgender patients
NCT ID NCT04478760
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study will determine the normal reference intervals for 27 common blood tests in transgender adults who have been on stable hormone therapy for at least a year. Currently, standard reference ranges are based on sex assigned at birth, which may not be accurate for transgender individuals. By recruiting 250 healthy transgender participants, researchers hope to provide doctors with better tools to interpret lab results and detect disease earlier.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide doctors with accurate reference ranges for common blood tests in transgender people on hormone therapy, leading to faster and more accurate disease detection.
- What could go wrong
- This is an observational study, not a treatment trial. It only establishes reference intervals and does not test any new therapy. Results may not apply to all transgender individuals or those on different hormone regimens.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
250 people
The number who actually took part.
- Started
-
Apr 2021
- Finished
-
May 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Healthy transgender adults who have been taking masculinising for feminising hormone therapy for at least 12 months.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Transgender or nonbinary people. * Aged 18 or older. * Taking testosterone or oestrogen therapy. * For 12 months or more. * Having routine hormone therapy monitoring at the clinic. Exclusion Criteria: * Unable to give informed consent (including participants who cannot communicate in English). * History of chronic liver disease, chronic kidney disease, diabetes, or severe cardiovascular disease (including myocardial infection, deep vein thrombosis, stroke and pulmonary embolism). * Blood test results that indicate severe disease. * Pregnant or within one year after childbirth. * Other conditions which could put participants at risk by participating, or which could influence the results of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hormone replacement therapy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Caldecot Centre, King's College Hospital, 15-22 Caldecot Road
London, SE5 9RS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a free app ease depression and suicide risk in trans young adults?
- Dentists may treat patients differently based on gender identity, study suggests
- Testosterone therapy may change how other drugs work in the body
- Menopause brain study: HRT's hidden effects on your nerves
- Transgender youth share what makes them say yes to research
- Healthy volunteers needed to Fine-Tune stroke diagnosis tests